Cyclerion Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -2.92%158.010.7%$1348.71m
PFEPfizer Inc. -0.89%33.520.9%$1215.71m
BMYBristol-Myers Squibb Co. -1.35%61.261.0%$862.91m
MRKMerck & Co., Inc. -2.73%72.580.7%$818.60m
ABBVAbbVie, Inc. 0.28%107.631.9%$796.41m
LLYEli Lilly & Co. 0.43%204.691.1%$749.41m
AZNAstraZeneca Plc -1.08%48.381.2%$499.92m
GSKGlaxoSmithKline Plc -2.24%33.610.2%$268.95m
NVSNovartis AG -0.87%85.960.2%$176.78m
SNYSanofi 0.20%45.890.2%$170.59m
VTRSViatris, Inc. -1.33%14.850.0%$143.27m
VERUVeru, Inc. -3.22%13.820.0%$113.90m
CVACCureVac NV 1.43%94.300.0%$107.31m
NVONovo Nordisk A/S -1.47%71.280.1%$90.64m
VYNEVYNE Therapeutics, Inc. -5.45%7.460.0%$88.66m

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.